{"slideshow_credits": null, "snippet": "Robert Ramnarine is accused of buying call options in ZymoGenetics, Pharmasset and Amylin Pharmaceuticals before they were acquired by Bristol-Myers Squibb.", "abstract": "Robert Ramnarine is accused of buying call options in ZymoGenetics, Pharmasset and Amylin Pharmaceuticals before they were acquired by Bristol-Myers Squibb.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "William", "role": "reported", "lastname": "ALDEN", "rank": 1, "organization": ""}], "original": "By WILLIAM ALDEN"}, "web_url": "http://dealbook.nytimes.com/2012/08/02/bristol-myers-executive-accused-of-insider-trading/", "lead_paragraph": null, "headline": {"main": "Bristol-Myers Executive Is Accused of Insider Trading", "print_headline": "Bristol Executive Is Accused of Inside Deals", "kicker": "DealBook"}, "_id": "501aab161c22dfde670b3d69", "word_count": "428", "multimedia": [], "pub_date": "2012-08-02T12:25:39Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Amylin Pharmaceuticals Inc", "rank": "1"}, {"name": "organizations", "value": "Bristol Myers Squibb Company", "rank": "2"}, {"name": "organizations", "value": "Securities and Exchange Commission", "rank": "3"}, {"name": "subject", "value": "Insider Trading", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}